Total Payments
$301,228
2024 Payments
$22,929
Companies
19
Transactions
168
Medicare Patients
15,059
Medicare Billing
$1.0M
Payment Breakdown by Category
Consulting$269,180 (89.4%)
Research$29,767 (9.9%)
Food & Beverage$2,282 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $269,180 | 119 | 89.4% |
| Unspecified | $29,767 | 14 | 9.9% |
| Food and Beverage | $2,282 | 35 | 0.8% |
Payments by Type
General
$271,461
154 transactions
Research
$29,767
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $179,792 | 105 | $0 (2021) |
| Boehringer Ingelheim RCV GmbH & Co KG | $61,585 | 4 | $0 (2023) |
| Stryker Corporation | $27,803 | 10 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $22,504 | 3 | $0 (2024) |
| Y-mAbs Therapeutics, Inc. | $6,813 | 10 | $0 (2023) |
| Penumbra, Inc. | $1,334 | 12 | $0 (2023) |
| Monteris Medical Corporation | $450.00 | 1 | $0 (2017) |
| Bracco Diagnostics Inc. | $204.31 | 5 | $0 (2024) |
| Thrombolex, Inc. | $138.30 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $124.95 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,929 | 8 | Regeneron Pharmaceuticals, Inc. ($22,504) |
| 2023 | $5,074 | 13 | Boehringer Ingelheim RCV GmbH & Co KG ($2,965) |
| 2022 | $15,779 | 8 | Stryker Corporation ($13,423) |
| 2021 | $115,699 | 66 | Merck Sharp & Dohme Corporation ($106,535) |
| 2020 | $92,538 | 31 | Boehringer Ingelheim RCV GmbH & Co KG ($58,620) |
| 2019 | $32,801 | 20 | Merck Sharp & Dohme Corporation ($24,434) |
| 2018 | $495.72 | 13 | Penumbra, Inc. ($327.00) |
| 2017 | $15,912 | 9 | Merck Sharp & Dohme Corporation ($15,203) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $5,640.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $14,818.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 09/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,046.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 08/27/2024 | Philips North America LLC | (BP3) Spectral CT 7500 (Device) | Food and Beverage | Cash or cash equivalent | $60.94 | General |
| Category: Medical Device | ||||||
| 04/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: Rare Disease | ||||||
| 04/17/2024 | Thrombolex, Inc. | Bashir Endovascular Catheter (Device) | Food and Beverage | Cash or cash equivalent | $138.30 | General |
| Category: Cardiovascular | ||||||
| 03/29/2024 | Bracco Diagnostics Inc. | Vueway (gadopiclenol) (Drug) | Food and Beverage | In-kind items and services | $48.18 | General |
| Category: Diagnostic Imaging | ||||||
| 01/26/2024 | Boston Scientific Corporation | EMBOLD Fibered (Device) | Food and Beverage | In-kind items and services | $52.96 | General |
| Category: Embold_PI | ||||||
| 12/14/2023 | Marinus Pharmaceuticals, Inc. | ZTALMY (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: SEIZURE DISORDERS | ||||||
| 11/22/2023 | Penumbra, Inc. | Indigo System (Device) | Food and Beverage | Cash or cash equivalent | $130.89 | General |
| Category: Peripheral Intervention | ||||||
| 11/17/2023 | Boehringer Ingelheim RCV GmbH & Co KG | — | Consulting Fee | Cash or cash equivalent | $2,965.00 | General |
| 10/21/2023 | Penumbra, Inc. | RED 72 (Device) | Food and Beverage | Cash or cash equivalent | $59.05 | General |
| Category: Neurointervention | ||||||
| 08/26/2023 | Bracco Diagnostics Inc. | Lumason (Drug) | Food and Beverage | In-kind items and services | $82.53 | General |
| Category: Diagnostic Imaging | ||||||
| 08/25/2023 | Bracco Diagnostics Inc. | Lumason (Drug) | Food and Beverage | In-kind items and services | $31.08 | General |
| Category: Diagnostic Imaging | ||||||
| 08/24/2023 | Bracco Diagnostics Inc. | Vueway (Drug) | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: Diagnostic Imaging | ||||||
| 07/20/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 07/20/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 05/24/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $480.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 02/16/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 02/16/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 01/19/2023 | Bracco Diagnostics Inc. | MultiHance (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Diagnostic Imaging | ||||||
| 12/16/2022 | Stryker Corporation | CASCADIA INTERBODY SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| Category: SPINE | ||||||
| 09/16/2022 | Stryker Corporation | CASCADIA INTERBODY SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $2,047.50 | General |
| Category: SPINE | ||||||
| 08/26/2022 | Stryker Corporation | CASCADIA INTERBODY SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $2,730.00 | General |
| Category: SPINE | ||||||
| 08/26/2022 | Stryker Corporation | CASCADIA INTERBODY SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $1,365.00 | General |
| Category: SPINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $22,504 | 3 |
| I(131)-BURTOMAB | Y-mAbs Therapeutics, Inc. | $5,073 | 5 |
| A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | Y-mAbs Therapeutics, Inc. | $1,740 | 5 |
| FLARE | Monteris Medical Corporation | $450.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 2,947 | 11,638 | $2.1M | $194,883 |
| 2022 | 40 | 3,192 | 13,091 | $2.5M | $254,922 |
| 2021 | 48 | 3,960 | 12,743 | $2.5M | $289,902 |
| 2020 | 59 | 4,960 | 14,836 | $2.5M | $285,066 |
Total Patients
15,059
Total Services
52,308
Medicare Billing
$1.0M
Procedure Codes
284
All Medicare Procedures & Services
284 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 123 | 126 | $209,821 | $28,851 | 13.8% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2023 | 178 | 179 | $239,389 | $21,561 | 9.0% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 89 | 89 | $94,990 | $12,143 | 12.8% |
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 332 | 373 | $187,992 | $11,574 | 6.2% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2023 | 89 | 90 | $110,592 | $10,848 | 9.8% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 83 | 87 | $115,188 | $7,370 | 6.4% |
| 0042T | Computed tomography (ct) of brain blood flow, volume, and timing of flow analysis with contrast | Facility | 2023 | 39 | 39 | $30,108 | $6,793 | 22.6% |
| 70498 | Ct scan of blood vessels of neck with contrast | Office | 2023 | 31 | 31 | $35,428 | $5,022 | 14.2% |
| 72146 | Mri scan of middle spinal canal without contrast | Office | 2023 | 42 | 42 | $55,566 | $4,482 | 8.1% |
| 72158 | Mri scan of lower spinal canal before and after contrast | Office | 2023 | 25 | 25 | $53,424 | $4,440 | 8.3% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 81 | 81 | $69,822 | $4,430 | 6.3% |
| 72131 | Ct scan of lower spine without contrast | Office | 2023 | 47 | 47 | $35,679 | $3,898 | 10.9% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 41 | 41 | $32,473 | $3,893 | 12.0% |
| 70491 | Ct scan of soft tissue of neck with contrast | Office | 2023 | 31 | 31 | $23,443 | $3,641 | 15.5% |
| 70450 | Ct scan head or brain without contrast | Office | 2023 | 48 | 49 | $24,336 | $3,629 | 14.9% |
| 70496 | Ct scan of blood vessels of head with contrast | Office | 2023 | 21 | 21 | $28,041 | $3,627 | 12.9% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 55 | 55 | $56,155 | $3,551 | 6.3% |
| 70543 | Mri scan of bone of eye socket, face, and/or neck before and after contrast | Office | 2023 | 11 | 12 | $32,091 | $3,234 | 10.1% |
| 72148 | Mri scan of lower spinal canal without contrast | Facility | 2023 | 60 | 60 | $51,720 | $3,218 | 6.2% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Office | 2023 | 13 | 13 | $36,298 | $3,156 | 8.7% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 48 | 48 | $58,944 | $3,099 | 5.3% |
| 70544 | Mri scan of blood vessels of head without contrast | Office | 2023 | 23 | 23 | $29,352 | $3,056 | 10.4% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 77 | 80 | $50,000 | $2,842 | 5.7% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 346 | 399 | $55,461 | $2,749 | 5.0% |
| 72141 | Mri scan of upper spinal canal without contrast | Facility | 2023 | 50 | 50 | $43,100 | $2,745 | 6.4% |
About Dr. Ryan Murtagh, MD
Dr. Ryan Murtagh, MD is a Diagnostic Radiology healthcare provider based in El Segundo, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1548396997.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Murtagh, MD has received a total of $301,228 in payments from pharmaceutical and medical device companies, with $22,929 received in 2024. These payments were reported across 168 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($269,180).
As a Medicare-enrolled provider, Murtagh has provided services to 15,059 Medicare beneficiaries, totaling 52,308 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 284 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Other Specialties Diagnostic Neuroimaging, Neuroradiology
- Location El Segundo, CA
- Active Since 02/27/2007
- Last Updated 01/20/2025
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1548396997
Products in Payments
- LENVIMA (Drug) $112,243
- PRADAXA (Drug) $58,620
- MK-4280 (Biological) $35,220
- KEYTRUDA (Biological) $23,800
- LIBTAYO (Biological) $22,504
- CASCADIA INTERBODY SYSTEM (Device) $18,813
- CASCADIA (Device) $8,080
- CAPRI CORPECTOMY CAGE SYSTEM (Device) $910.00
- Indigo (Device) $871.62
- NeuroBlate (Drug) $450.00
- Indigo System (Device) $277.89
- Bashir Endovascular Catheter (Device) $138.30
- ACE (Device) $125.00
- ULTOMIRIS (Biological) $124.95
- proGAV 2.0 (Device) $116.88
- Lumason (Drug) $113.61
- EKOSONIC (Device) $87.60
- RNS System (Device) $78.74
- (BP3) Spectral CT 7500 (Device) $60.94
- RED 72 (Device) $59.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in El Segundo
Bruce Zwiebel, Md, MD
Diagnostic Radiology — Payments: $54,373
Diagnostic Radiology $54,373
Dr. Eddie Hyatt, M.d, M.D
Diagnostic Radiology — Payments: $19,344
Diagnostic Radiology $19,344
Dr. Kamal Massis, M.d, M.D
Diagnostic Radiology — Payments: $14,498
Diagnostic Radiology $14,498
Rajendra Kedar, Md, MD
Diagnostic Radiology — Payments: $12,924
Diagnostic Radiology $12,924
Dr. Laurence Grundy, Md, MD
Diagnostic Radiology — Payments: $12,864
Diagnostic Radiology $12,864
Dr. Samuel Shube, M.d, M.D
Diagnostic Radiology — Payments: $10,758
Diagnostic Radiology $10,758